Platelet x CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer

被引:22
作者
Miyamoto, Ryoichi [1 ]
Oda, Tatsuya [1 ]
Hashimoto, Shinji [1 ]
Kurokawa, Tomohiro [1 ]
Kohno, Keisuke [1 ]
Akashi, Yoshimasa [1 ]
Ohara, Yusuke [1 ]
Yamada, Keiichi [1 ]
Enomoto, Tsuyoshi [1 ]
Ohkohchi, Nobuhiro [1 ]
机构
[1] Univ Tsukuba, Dept Surg, Div Gastroenterol & Hepatobiliary Surg & Organ Tr, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan
基金
日本学术振兴会;
关键词
thrombocytosis; pancreatic cancer; platelet; CRP; inflammatory response; prognostic factor; DUCTAL ADENOCARCINOMA; VENOUS THROMBOEMBOLISM; CURATIVE RESECTION; RECTAL-CANCER; FREE SURVIVAL; THROMBOCYTOSIS; COUNTS; TRIAL; RISK; GEMCITABINE;
D O I
10.1097/MPA.0000000000000697
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: Thrombocytosis in patients with various cancers has been considered a parameter for poor prognosis; however, its contribution to pancreatic cancer remains controversial. Methods: Potential preoperative prognostic parameters (platelets, neutrophils, lymphocytes, the platelet-lymphocyte ratio, the neutrophil-lymphocyte ratio, the serum C-reactive protein [CRP], and carbohydrate antigen 19-9) were retrospectively analyzed in 95 patients with pancreatic cancer. Cutoff values were defined according to receiver operating characteristic curve analysis, and median survival times (MSTs) were compared. Results: Median survival times (days) significantly differed according to platelet count (high [552] vs low [735], P = 0.017), CRP (high [471] vs low [750], P = 0.001), and carbohydrate antigen 19-9 level (high [639] vs low [765], P = 0.021), whereas there was no difference in the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio. Multivariate analysis identified thrombocytosis (hazard ratio, 2.015) and CRP level (hazard ratio, 1.771) as independent prognostic factors. The combinatory effects of platelets and the inflammatory response using a platelet x CRP multiplier value could effectively distinguished the MSTs (days) of patients with pancreatic cancer (high [482] vs low [812], P < 0.001). Conclusions: Thrombocytosis and CRP influenced pancreatic cancer patient prognosis. Platelet x CRP multiplier is assumed as a useful parameter that reflects the contribution of activated platelets to cancer progression.
引用
收藏
页码:35 / 41
页数:7
相关论文
共 50 条
[41]   Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer [J].
Oshima, Minoru ;
Okano, Keiichi ;
Suto, Hironobu ;
Ando, Yasuhisa ;
Kamada, Hideki ;
Masaki, Tsutomu ;
Takahashi, Shigeo ;
Shibata, Toru ;
Suzuki, Yasuyuki .
BMC GASTROENTEROLOGY, 2020, 20 (01)
[42]   Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy [J].
Kaneko, Manabu ;
Nozawa, Hiroaki ;
Sasaki, Kazuhito ;
Hongo, Kumiko ;
Hiyoshi, Masaya ;
Tada, Noriko ;
Murono, Koji ;
Nirei, Takako ;
Kawai, Kazushige ;
Sunami, Eiji ;
Tsuno, Nelson H. ;
Kitayama, Joji .
ONCOLOGY, 2012, 82 (05) :261-268
[43]   Preoperative Platelet to Lymphocyte Ratio as a Prognostic Factor for Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis [J].
Riauka, Romualdas ;
Ignatavicius, Povilas ;
Barauskas, Giedrius .
DIGESTIVE SURGERY, 2020, 37 (06) :447-455
[44]   Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study outcomes of resectable pancreatic cancer [J].
Park, Hyeong Min ;
Park, Sang-Jae ;
Han, Sung-Sik ;
Kim, Seoung Hoon .
BMC CANCER, 2019, 19 (01)
[45]   Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer [J].
Tajima, Hidehiro ;
Ohta, Tetsuo ;
Okazaki, Mitsuyoshi ;
Yamaguchi, Takahisa ;
Ohbatake, Yoshinao ;
Okamoto, Koichi ;
Nakanuma, Shinichi ;
Kinoshita, Jun ;
Makino, Isamu ;
Nakamura, Keishi ;
Miyashita, Tomoharu ;
Takamura, Hiroyuki ;
Ninomiya, Itasu ;
Fushida, Sachio ;
Nakamura, Hiroyuki .
MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (02) :157-166
[46]   A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery? [J].
Nakamura, Toru ;
Asano, Toshimichi ;
Okamura, Keisuke ;
Tsuchikawa, Takahiro ;
Murakami, Soichi ;
Kurashima, Yo ;
Ebihara, Yuma ;
Noji, Takehiro ;
Nakanishi, Yoshitsugu ;
Tanaka, Kimitaka ;
Shichinohe, Toshiaki ;
Hirano, Satoshi .
JOURNAL OF GASTROINTESTINAL SURGERY, 2019, 23 (05) :990-996
[47]   Increased platelet-to-lymphocytes ratio is associated with poor long-term prognosis in patients with pancreatic cancer after surgery [J].
Yu, Jinming ;
Ding, Zhaoyan ;
Yang, Yuanming ;
Liu, Shanli .
MEDICINE, 2018, 97 (25)
[48]   Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer [J].
Plvi Vento ;
Harri Mustonen ;
Timo Joensuu ;
Pivi Krkkinen ;
Eero Kivilaakso ;
Tuula Kiviluoto .
World Journal of Gastroenterology, 2007, (21) :2945-2951
[49]   Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer [J].
Vento, Palvi ;
Mustonen, Harri ;
Joensuu, Timo ;
Kaerkkaeinen, Paivi ;
Kivilaakso, Eero ;
Kiviluoto, Tuula .
WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (21) :2945-2951
[50]   Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis [J].
Yoon, Min Sung ;
Lee, Hee Seung ;
Kang, Chang Moo ;
Lee, Woo Jung ;
Keum, Jiyoung ;
Sung, Min Je ;
Kim, Seungseob ;
Park, Mi-Suk ;
Jo, Jung Hyun ;
Chung, Moon Jae ;
Park, Jeong Youp ;
Park, Seung Woo ;
Song, Si Young ;
Hwang, Ho Kyoung ;
Bang, Seungmin .
GUT AND LIVER, 2021, :118-128